15, 16, 17, 18 Two HDAC inhibitors, SAHA and romidepsin, are US Food and Drug Administration (FDA) approved for the treatment of cutaneous T-cell lymphoma.19 MI192, a novel HDAC3-selective inhibitor, was found to be beneficial for rheumatoid arthritis in vitro with marginal toxicity.20 However, the effects of MI192 in CCA have not yet been studied. The gene discussed is HDAC3; the disease is cholangiocarcinoma.